Anna F Rumbach1, Andrew Blitzer2,3, Steven J Frucht2, Kristina Simonyan2. 1. School of Health and Rehabilitation Sciences, Speech Pathology, University of Queensland, Brisbane, Queensland, Australia. 2. Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York, U.S.A. 3. Head and Neck Surgical Group, New York, New York, U.S.A.
Abstract
OBJECTIVES/HYPOTHESIS: Spasmodic dysphonia (SD) is a task-specific laryngeal dystonia that affects speech production. Co-occurring voice tremor (VT) often complicates the diagnosis and clinical management of SD. Treatment of SD and VT is largely limited to botulinum toxin injections into laryngeal musculature; other pharmacological options are not sufficiently developed. STUDY DESIGN: Open-label study. METHODS: We conducted an open-label study in 23 SD and 22 SD/VT patients to examine the effects of sodium oxybate (Xyrem), an oral agent with therapeutic effects similar to those of alcohol in these patients. Blinded randomized analysis of voice and speech samples assessed symptom improvement before and after drug administration. RESULTS:Sodium oxybate significantly improved voice symptoms (P = .001) primarily by reducing the number of SD-characteristic voice breaks and severity of VT. Sodium oxybate further showed a trend for improving VT symptoms (P = .03) in a subset of patients who received successful botulinum toxin injections for the management of their SD symptoms. The drug's effects were observed approximately 30 to 40 minutes after its intake and lasted about 3.5 to 4 hours. CONCLUSIONS: Our study demonstrated that sodium oxybate reduced voice symptoms in 82.2% of alcohol-responsive SD patients both with and without co-occurring VT. Our findings suggest that the therapeutic mechanism of sodium oxybate in SD and SD/VT may be linked to that of alcohol, and as such, sodium oxybate might be beneficial for alcohol-responsive SD and SD/VT patients. LEVEL OF EVIDENCE: 4 Laryngoscope, 127:1402-1407, 2017.
RCT Entities:
OBJECTIVES/HYPOTHESIS: Spasmodic dysphonia (SD) is a task-specific laryngeal dystonia that affects speech production. Co-occurring voice tremor (VT) often complicates the diagnosis and clinical management of SD. Treatment of SD and VT is largely limited to botulinum toxin injections into laryngeal musculature; other pharmacological options are not sufficiently developed. STUDY DESIGN: Open-label study. METHODS: We conducted an open-label study in 23 SD and 22 SD/VTpatients to examine the effects of sodium oxybate (Xyrem), an oral agent with therapeutic effects similar to those of alcohol in these patients. Blinded randomized analysis of voice and speech samples assessed symptom improvement before and after drug administration. RESULTS:Sodium oxybate significantly improved voice symptoms (P = .001) primarily by reducing the number of SD-characteristic voice breaks and severity of VT. Sodium oxybate further showed a trend for improving VT symptoms (P = .03) in a subset of patients who received successful botulinum toxin injections for the management of their SD symptoms. The drug's effects were observed approximately 30 to 40 minutes after its intake and lasted about 3.5 to 4 hours. CONCLUSIONS: Our study demonstrated that sodium oxybate reduced voice symptoms in 82.2% of alcohol-responsive SDpatients both with and without co-occurring VT. Our findings suggest that the therapeutic mechanism of sodium oxybate in SD and SD/VT may be linked to that of alcohol, and as such, sodium oxybate might be beneficial for alcohol-responsive SD and SD/VTpatients. LEVEL OF EVIDENCE: 4 Laryngoscope, 127:1402-1407, 2017.
Authors: J S Perlmutter; M K Stambuk; J Markham; K J Black; L McGee-Minnich; J Jankovic; S M Moerlein Journal: J Neurosci Date: 1997-01-15 Impact factor: 6.167
Authors: Christy L Ludlow; Charles H Adler; Gerald S Berke; Steven A Bielamowicz; Andrew Blitzer; Susan B Bressman; Mark Hallett; H A Jinnah; Uwe Juergens; Sandra B Martin; Joel S Perlmutter; Christine Sapienza; Andrew Singleton; Caroline M Tanner; Gayle E Woodson Journal: Otolaryngol Head Neck Surg Date: 2008-10 Impact factor: 3.497
Authors: Codrin Lungu; Laurie Ozelius; David Standaert; Mark Hallett; Beth-Anne Sieber; Christine Swanson-Fisher; Brian D Berman; Nicole Calakos; Jennifer C Moore; Joel S Perlmutter; Sarah E Pirio Richardson; Rachel Saunders-Pullman; Laura Scheinfeldt; Nutan Sharma; Roy Sillitoe; Kristina Simonyan; Philip A Starr; Anna Taylor; Jerrold Vitek Journal: Neurology Date: 2020-02-25 Impact factor: 9.910
Authors: Christopher R Honey; Marie T Krüger; Timóteo Almeida; Linda A Rammage; Mandeep S Tamber; Murray D Morrison; Anujan Poologaindran; Amanda Hu Journal: Neurosurgery Date: 2021-06-15 Impact factor: 4.654
Authors: Kristina Simonyan; Julie Barkmeier-Kraemer; Andrew Blitzer; Mark Hallett; John F Houde; Teresa Jacobson Kimberley; Laurie J Ozelius; Michael J Pitman; Robert Mark Richardson; Nutan Sharma; Kristine Tanner Journal: Neurology Date: 2021-04-15 Impact factor: 11.800
Authors: Johanna Junker; Valerie Brandt; Brian D Berman; Marie Vidailhet; Emmanuel Roze; Anne Weissbach; Cynthia Comella; Irene A Malaty; Joseph Jankovic; Mark S LeDoux; Alfredo Berardelli; Richard Barbano; Stephen G Reich; Joel S Perlmutter; H A Jinnah; Norbert Brüggemann Journal: Neurology Date: 2018-10-19 Impact factor: 9.910